FIRST LINE 5-FU-BASED CHEMOTHERAPY WITH/WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: TISSUE BIOMARKER CANDIDATES

• Главные авторы: Assia Konsoulova (Автор), Ivan Donev (Автор), Nikolay Conev (Автор), Sonya Draganova (Автор), Nadezhda Petrova (Автор), Eleonora Dimitrova (Автор), Hristo Popov (Автор), Kameliya Bratoeva (Автор), Petar Ghenev (Автор)
• Формат: ‌
• Опубликовано: Peytchinski Publishing, 2016-03-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Purpose: Colorectal cancer is the second leading cause of cancer mortality in the USA. According to Bulgarian National Statistics Institute, 2370 colon and 1664 rectal cancer cases were diagnosed in 2012 with total number of patients 29995. Adding bevacizumab to chemotherapy in patients with metasta...